Drug intelligence / Profile preview

NDX-3324

Development stage: Phase 2
Lead developer: NexEos Bio
Modality: Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics
Administration: Oral

Overview

NDX-3324 is a novel, non-invasive imaging agent developed for the diagnosis, treatment monitoring, and management of **Eosinophilic Esophagitis (EoE)**. It is a contrast agent used in radiopharmaceutical imaging to help detect and monitor eosinophil-driven inflammation in the esophagus. The drug is administered orally and is currently in **Phase 2** clinical trials.

Targets

PRG2 (Major basic protein 1)

Beyond the preview

Go deeper on NDX-3324.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NDX-3324.

Explore the full profile